GAIA BIOMEDICINE & TREEFROG THERAPEUTICS ANNOUNCE COLLABORATION FOR THE EXPANSION OF ALLOGENEIC NK-LIKE CELLS AGAINST SOLID TUMORS
FUKUOKA, Japan, and BORDEAUX, France / Feb. 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells.
“With 3 ongoing clinical trials, GAIA is one of the world’s most advanced cell therapy companies in the field of solid tumors. They have a very compelling allogeneic strategy, which relies on GAIA-102 NK-like cells – a specific population of immune cells isolated from healthy donor blood samples that exhibit strong anti-tumor cytotoxic potency. Our Japanese team is very excited to start collaborating with GAIA scientists, and we strongly believe that GAIA’s approach, combined with the C-Stem™ platform, could lead to fast and broad patient access to adoptive cell therapies against solid tumors”.
Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics
“TreeFrog has a very interesting biomimetic approach to cell culture. In our case, the C-Stem technology could enable the expansion of NK-like immune cells in conventional stirred-tank bioreactors, while maintaining the desired phenotype. As we keep advancing more adoptive cell therapy programs to the clinic, C-Stem™ could constitute an alternative platform for large-scale GMP manufacturing.”
Kazuyuki Kuramori, President and CEO of GAIA BioMedicine
About GAIA BioMedicine
GAIA BioMedicine, Inc., founded in 2015 by Prof Yoshikazu Yonemitsu as a spin-off venture of Kyushu University, is a technology-driven biopharmaceutical company specializing in cell therapies for cancer using NK cells.
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. Bringing together over 100 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance a pipeline of stem cell-based therapies in immuno-oncology and regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, with the aim of driving the adoption of the C-StemTM platform and establish strategic alliances with leading academic, biotech and industry players in the field of cell therapy.
Kazuyuki Kuramori, President, CEO
Pierre-Emmanuel Gaultier, Head of Communication
+ 33 6 45 77 42 58